SOURCE: Industrial Info Resources

Industrial Info Resources

December 03, 2010 05:30 ET

Compassionate, Cash-Rich Pharmaceutical Companies Prepare for Rocky Road Ahead, an Industrial Info News Alert

SUGAR LAND, TX--(Marketwire - December 3, 2010) - Researched by Industrial Info Resources (Sugar Land, Texas) -- The Pharmaceutical Industry has observed major changes over the past year, with performance being affected by factors such as listless prescription trends and escalating generic competition. Big Pharma's novel products are not expected to generate the same level of profit as current products that are losing patent protection. With revenue growth becoming stagnant, companies have been resorting to cost-cutting, share repurchasing, cash conservation, and mergers and acquisitions to drive bottom-line growth.

There has been a flurry of merger and acquisition activity over the past year. Major transactions include Pfizer's (NYSE:PFE) (New York, New York) acquisition of Wyeth , Johnson & Johnson's (NYSE:JNJ) (New Brunswick, New Jersey) acquisition of Mentor Corporation, Abbott Laboratories' (NYSE:ABT) (Abbott Park, Illinois) acquisition of Advanced Medical Optics and the pharmaceuticals business of Solvay Group, and the merger of Merck & Company (NYSE:MRK) (Whitehouse Station, New Jersey) and Schering-Plough.

For details, view the entire article by subscribing to Industrial Info's Premium Industry News at, or browse other breaking industrial news stories at

Industrial Info Resources (IIR) is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. IIR's quality-assurance philosophy, the Living Forward Reporting Principle™, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. For more information send inquiries to or visit us at

Follow us on: Facebook - Twitter - LinkedIn - Vimeo